Naproxen Emerges a Winner In Relieving Osteoarthritis Pain

Naproxen Drug, still a better pain reliever than other non surgical pain reducing options for osteoarthritis knee, finds a new study The findings of this study are published in Journal of The American Academy of Orthopaedic Surgeons.

Nonsurgical treatments for knee OA supported by previous research evidence include strength training, low-impact aerobic exercises, NSAIDs, and weight loss in individuals with a body mass index over 25. This new research analyzed data from multiple trials to determine the relative effectiveness of various nonsurgical treatments for knee OA.

Naproxen Could Prevent Bladder Cancer
Mice studies have revealed that naproxen reduced the incidence of bladder cancer by 75 percent in rats, and intermittent dosing with naproxen was highly effective to reduce gastric toxicity.

‘Naproxen was ranked the most effective individual knee OA treatment for improving both pain and function followed by cortisone injections, PRP Injections, ibuprofen and celecoxib.’

Tweet it Now

The treatments that were compared and ranked included acetaminophen; ibuprofen; intra-articular (IA) or joint injections of cortisone; platelet-rich plasma (PRP); hyaluronic acid (HA); several NSAIDs, such as naproxen, celecoxib, and diclofenac; and both oral and IA placebo.

"This is the first comprehensive mixed-comparison analysis comparing best-evidence scientific research and excluding lower quality studies that can bias the outcomes," said lead author and orthopaedic surgeon David Jevsevar, MD, MBA. "Using a statistical ranking technique, we worked to provide evidence regarding which of the most common NSAIDs are most likely to decrease pain and improve function, and we attempted to fill in the gaps in evidence for more inconclusive treatments such as HA, PRP, and corticosteroids."

Authors analyzed 53 randomized controlled trials that examined knee OA treatments for at least 28 days and included a minimum of 30 participants per study group. Knee OA treatments were ranked on a scale of one to five, with one being the most effective. They found the following:

Popular Painkiller Naproxen Poses Same Heart Risk as Rival Painkillers
The popular painkiller naproxen, manufactured by German drug giant Bayer and sold under the brand name Aleve, has the same cardiovascular risks as rival medicines, US drug regulators said.

For pain reduction, cortisone injections provided the greatest short-term (4 to 6 weeks) pain relief, followed by ibuprofen, PRP injections, naproxen, and celecoxib.

Naproxen ranked the highest for probability for improving function, followed by diclofenac, celecoxib, ibuprofen, and PRP injections. Naproxen was ranked the most effective individual knee OA treatment for improving both pain and function followed by cortisone injections, PRP injections, ibuprofen and celecoxib.

Anti-inflammatory Drug Helps Combat Flu
Naproxen - pain reliever was found to exhibit antiviral activity against influenza A virus, find researchers.

HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function. An analysis of 12 articles also found that results with HA are not significantly different from those with IA placebo for treatment of knee OA.

"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed," explained Dr. Jevsevar. "While the information in this analysis is helpful to physicians, patients also can benefit from these findings and use it with their doctors to weigh all possible treatment options."

Fever Drugs Raise Risk of Acute Kidney Injury in Kids
Sick children who are given common fever medications such as ibuprofen and naproxen are at greater risk of developing acute kidney injury, warn researchers.

Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.

Source-Eurekalert